- Company
- ST Pharm’s new cash cow ‘oligonucleotide’
- by Kim, Jin-Gu Sep 28, 2021 05:54am
- The oligonucleotide API business has become a major business of ST Pharm. The company has signed many deals over the past three years and the expansion and expectations for contract extensions have also greatly contributed to improving the company’s performance. Experts expect the oligonucleotide API business to stay as a cash cow for ST
- Policy
- Domestic venture introduces new imported breast cancer drug
- by Lee, Tak-Sun Sep 28, 2021 05:54am
- As domestic startup is imminent to introduce new breast cancer drug from overseas, Geo-Young is in charge of third-party logistics of the drug, drawing attention. This is because it is different from the existing anticancer drug distribution method that foreign pharmaceutical companies and large domestic pharmaceutical companies used to suppl
- Policy
- Will Rinvoq be approved for atopic dermatitis?
- by Lee, Tak-Sun Sep 28, 2021 05:54am
- Whether AbbVie Korea’s ‘Rinvoq SR,’ which has been prescribed with reimbursement as an oral rheumatoid arthritis treatment since last year, will add an indication for atopic dermatitis, is gaining attention. The industry believes it is highly possible, as the higher-dose formulation is soon to be approved in Korea, and the drug was app
- Policy
- Pfizer vaccine for 1.67 million doses, about to be discarded
- by Lee, Jeong-Hwan Sep 28, 2021 05:53am
- Among the COVID-19 vaccines supplied in Korea, the vaccine with the most imminent expiration date was the Pfizer vaccine. Pfizer had about 1.67 million in stock and Janssen had about 720,000 in stock for supplies that remained within a month of expiration. Kang Ki-yoon, a member of the People Power Party, made the remarks in a data submitted
- Policy
- 129 drug price reduction starting in October
- by Kim, Jung-Ju Sep 28, 2021 05:53am
- Drugs that sell a lot or have a high price range will be lowered as of the 1st of next month. It will be reduced by up to 10%. It also included seven Choline alfoscerates that negotiated the redemption of drug costs for clinical revaluation. AstraZeneca's Lynparza 50mg, Kadcyla 100mg, and Kadcyla 160mg succeeded in risk-sharing contracts (RSA),
- Company
- First progress to SGLT2i combo reimb. made in 3 years
- by Eo, Yun-Ho Sep 27, 2021 05:52am
- Patients in Korea have come one step closer to receiving reimbursement extensions to SGLT-2 inhibitor combos. This is the first progress that has been made in three years. According to industry sources, the diabetes expert committee that was convened by the Health Insurance Review and Assessment Service earlier this month concluded in the
- Policy
- Is the third Avastin biosimilar coming out?
- by Lee, Tak-Sun Sep 27, 2021 05:51am
- Attention is focusing on whether another company will release an Avastin (Bevacizumab) biosimilar approved by Samsung Bioepis and Pfizer. This is because it was found that a new item was approved by the MFDS in August. If the item is approved, a total of four items, including the original Avastin by Roche and three biosimilars, are expect
- Company
- Eliquis generics pull out from market after losing suit
- by Kim, Jin-Gu Sep 27, 2021 05:51am
- With major Eliquis (apixaban) generics products removed from the insurance benefit list after losing the patent suit, the Eliquis generics have now completely withdrawn from the market. As a result, the only dispute left between the original and generic companies for Eliquis is the claims for damages, and a fierce legal battle is expecte
- Policy
- The per capita GDP reference standard was deleted from ICER
- by Lee, Hye-Kyung Sep 27, 2021 05:51am
- The per capita GDP phrase was deleted from the ICER threshold used in the economic evaluation process of the first stage of new drug benefits. Although it has been changed to refer to the results of the existing deliberation, the phrase GDP per capita has been deleted, and the application of ICER values, one of the pharmaceutical industry's long
- Company
- When does Sputnik ship in Korea?
- by Kim, Jin-Gu Sep 27, 2021 05:51am
- Shipment of the domestic finished product of the COVID-19 vaccine Sputnik developed in Russia will begin as early as next month. The consortium centered on Korus has already secured 10 million finished products, and the Huons Global Consortium plans to start producing finished products by the end of this year. ◆Prospects of shipment
